Medicine |
Indication |
alirocumab |
Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk |
atomoxetine |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older |
azathioprine |
For the treatment of adults with inflammatory rheumatic, bowel and skin diseases |
aztreonam lysine (Cayston) |
Suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis aged six years and older |
bempedoic acid |
Primary hypercholesterolaemia or mixed dyslipidaemia, where maximally-tolerated lipid-lowering therapy has failed to achieve target LDL cholesterol |
buprenorphine |
Maintenance treatment of opioid dependence |
ciclosporin (Capimune) |
Inflammatory rheumatic and skin conditions |
ciclosporin (Neoral) |
Solid organ transplant in adult patients |
cinacalcet |
Secondary hyperparathyroidism in patients with end stage renal disease on dialysis |
colistimethate sodium |
Chronic pulmonary Pseudomonas aeruginosa infection in children and adults with cystic fibrosis and adults with non-cystic fibrosis bronchiectasis |
dexamfetamine and lisdexamfetamine |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 years and older |
dornase alfa |
Management of cystic fibrosis patients with a forced vital capacity (FVC) of greater than 40% of predicted and over 5 years of age to improve pulmonary function |
Erythropoiesis Stimulating Agents (ESAs) |
Chronic renal failure |
evolocumab |
Hypercholesterolaemia and elevated (atherosclerotic) cardiovascular risk |
Feminising endocrine treatment (Estradiol and GnRHa) |
Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds |
guanfacine |
Attention deficit hyperactivity disorder (ADHD) in children aged 6 to 18 years |
hydroxycarbamide |
Myeloproliferative neoplasms including essential thrombocythaemia, polycythaemia vera, myelofibrosis and chronic myelomonocytic leukaemia |
hydroxychloroquine |
Inflammatory rheumatic diseases |
ketamine |
Complex pain in palliative care patients |
lanreotide long acting and octreotide long acting (somatostatin analogues) |
Acromegaly
|
lanreotide and octreotide (somatostatin analogues) |
Neuroendocrine tumours |
leflunomide |
Inflammatory rheumatic diseases |
liraglutide |
Weight loss |
Masculinising endocrine treatment (Testosterone) |
Gender dysphoria/incongruence after assessment at the GIC for over 18 year olds |
mercaptopurine |
Inflammatory bowel disease (ulcerative colitis and Crohn’s disease) |
methotrexate (oral and subcutaneous) |
Adults with inflammatory rheumatic, bowel and skin conditions |
methotrexate (oral and subcutaneous) |
Paediatric inflammatory rheumatic and bowel conditions |
methylphenidate |
Attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older |
mycophenolate mofetil (MMF) and mycophenolic acid (Myfortic) |
Solid organ transplant adult patients |
mycophenolate mofetil (MMF) |
For non-transplant indications |
mycophenolic acid |
Uveitis |
penicillamine |
Inflammatory rheumatic diseases |
riluzole |
Amyotrophic lateral sclerosis (ALS) motor neurone disease |
roxadustat |
Management of symptomatic anaemia in patients with chronic renal failure |
somatropin (recombinant human growth hormone) |
Adult hypopituitarism |
somatropin (recombinant human growth hormone) |
Growth failure/disturbance in children |
sulfasalazine |
Inflammatory rheumatic diseases |
Test SCA |
Test SCA Lothian |
tacrolimus (Adoport, Prograf, Advagraf) |
Solid organ transplants in adult patients |
tacrolimus |
Uveitis |
tenofovir disoproxil fumarate |
Chronic hepatitis B infection in adults |
tobramycin |
Chronic pulmonary Pseudomonas Aeruginosa infection in children and adults with cystic fibrosis |
valganciclovir |
Prevention of CMV infection in solid organ transplant |